Citations

Showing 10 of 108083 citations.

In Vitro Enhanced Osteogenic Potential of Human Mesenchymal Stem Cells Seeded in a Poly (Lactic-co-Glycolic) Acid Scaffold: A Systematic Review
Maita, Karla C. , Torres‐Guzman, Ricardo A. , Quiñones‐Hinojosa, Alfredo , Torres, Ricardo A , Ávila, Francisco R. , Sarabia-Estrada, Rachel , Zubair, Abba C. , Forte, Antonio J.

Mayo Clinic

Craniomaxillofacial Trauma & Reconstruction | February 13, 2023 | Volume: 17 | Issue: 1 | Pages: 61-73

10.1177/19433875231157454 | PMID 38371215 Get It

Study Design Human bone marrow stem cells (hBMSCs) and human adipose-derived stem cells (hADSCs) have demonstrated the capability to regenerate bone once they have differentiated into osteoblasts. Objective This systematic review aimed to evaluate the in vitro osteogenic differentiation potential of these cells when seeded in a poly (lactic- co-glycolic) acid (PLGA) scaffold. Methods A literature search of 4 databases following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was conducted in January 2021 for studies evaluating the osteogenic differentiation potential of hBMSCs and hADSCs seeded in a PLGA scaffold. Only in vitro models were included. Studies in languages other than English were excluded. Results A total of 257 studies were identified after the removal of duplicates. Seven articles fulfilled our inclusion and exclusion criteria. Four of these reviews used hADSCs and three used hBMSCs in the scaffold. Upregulation in osteogenic gene expression was seen in all the cells seeded in a 3-dimensional scaffold compared with 2-dimensional films. High angiogenic gene expression was found in hADSCs. Addition of inorganic material to the scaffold material affected cell performance. Conclusions Viability, proliferation, and differentiation of cells strongly depend on the environment where they grow. There are several factors that can enhance the differentiation capacity of stem cells. A PLGA scaffold proved to be a biocompatible material capable of boosting the osteogenic differentiation potential and mineralization capacity in hBMSCs and hADSCs.
Neuro-Ophthalmic Literature Review
Bellows, David A., Chen, John J. , Cheng, Hui‐Chen , MacIntosh, Peter W., Vaphiades, Michael S., Chen, John J , Chan, Noel C. Y. , McClelland, Collin M. , Weber, Konrad Peter , Zhang, Xiaojun

Mayo Clinic

Neuro-Ophthalmology | February 13, 2023 | Volume: 47 | Issue: 1 | Pages: 54-61

10.1080/01658107.2022.2155453 Get It

Predicting amyloid PET and tau PET stages with plasma biomarkers
Jack, Clifford R. , Wiste, Heather J. , Figdore, Daniel J. , Schwarz, Christopher G. , Lowe, Val J. , Ramanan, Vijay K. , Vemuri, Prashanthi , Mielke, Michelle M. , Knopman, David S. , Graff‐Radford, Jonathan , Kantarci, Kejal , Gunter, Jeffrey L. , Therneau, Terry M. , Petersen, Ronald C. , Knopman, David S. , Figdore, Dan J, Schwarz, Christopher G , Ramanan, Vijay K , Vemuri, Prashanthi , Mielke, Michelle M , Graff-Radford, Jonathan , Kantarci, Kejal , Cogswell, Petrice M , Jack, Clifford R , Figdore, Daniel J , Algeciras‐Schimnich, Alicia , Boeve, Bradley F. , Cogswell, Petrice M. , Senjem, Matthew L.

Mayo Clinic

Brain | February 13, 2023 | Volume: 146 | Issue: 5 | Pages: 2029-2044

10.1093/brain/awad042 | PMID 36789483 Get It

Abstract Staging the severity of Alzheimer’s disease pathology using biomarkers is useful for therapeutic trials and clinical prognosis. Disease staging with amyloid and tau PET has face validity; however, this would be more practical with plasma biomarkers. Our objectives were, first, to examine approaches for staging amyloid and tau PET and, second, to examine prediction of amyloid and tau PET stages using plasma biomarkers. Participants (n = 1136) were enrolled in either the Mayo Clinic Study of Aging or the Alzheimer’s Disease Research Center; had a concurrent amyloid PET, tau PET and blood draw; and met clinical criteria for cognitively unimpaired (n = 864), mild cognitive impairment (n = 148) or Alzheimer’s clinical syndrome with dementia (n = 124). The latter two groups were combined into a cognitively impaired group (n = 272). We used multinomial regression models to estimate discrimination [concordance (C) statistics] among three amyloid PET stages (low, intermediate, high), four tau PET stages (Braak 0, 1–2, 3–4, 5–6) and a combined amyloid and tau PET stage (none/low versus intermediate/high severity) using plasma biomarkers as predictors separately within unimpaired and impaired individuals. Plasma analytes, p-tau181, Aβ1–42 and Aβ1–40 (analysed as the Aβ42/Aβ40 ratio), glial fibrillary acidic protein and neurofilament light chain were measured on the HD-X Simoa Quanterix platform. Plasma p-tau217 was also measured in a subset (n = 355) of cognitively unimpaired participants using the Lilly Meso Scale Discovery assay. Models with all Quanterix plasma analytes along with risk factors (age, sex and APOE) most often provided the best discrimination among amyloid PET stages (C = 0.78–0.82). Models with p-tau181 provided similar discrimination of tau PET stages to models with all four plasma analytes (C = 0.72–0.85 versus C = 0.73–0.86). Discriminating a PET proxy of intermediate/high from none/low Alzheimer’s disease neuropathological change with all four Quanterix plasma analytes was excellent but not better than p-tau181 only (C = 0.88 versus 0.87 for unimpaired and C = 0.91 versus 0.90 for impaired). Lilly p-tau217 outperformed the Quanterix p-tau181 assay for discriminating high versus intermediate amyloid (C = 0.85 versus 0.74) but did not improve over a model with all Quanterix plasma analytes and risk factors (C = 0.85 versus 0.83). Plasma analytes along with risk factors can discriminate between amyloid and tau PET stages and between a PET surrogate for intermediate/high versus none/low neuropathological change with accuracy in the acceptable to excellent range. Combinations of plasma analytes are better than single analytes for many staging predictions with the exception that Quanterix p-tau181 alone usually performed equivalently to combinations of Quanterix analytes for tau PET discrimination.
Rate Modulation Abilities in Acquired Motor Speech Disorders
Utianski, Rene L. , Duffy, Joseph R. , Martin, Peter R. , Clark, Heather M. , Stierwalt, Julie A. G., Botha, Hugo , Ali, Farwa , Whitwell, Jennifer L. , Josephs, Keith A. , Utianski, Rene L , Botha, Hugo , Clark, Heather M , Duffy, Joseph R , Whitwell, Jennifer L.

Mayo Clinic

Journal of Speech, Language, and Hearing Research | February 13, 2023 | Volume: 66 | Issue: 8S | Pages: 3194-3205

10.1044/2022_jslhr-22-00286 | PMID 36780318 Get It

Purpose: The purpose of this study was to describe, compare, and understand speech modulation capabilities of patients with varying motor speech disorders (MSDs) in a paradigm in which patients made highly cued attempts to speak faster or slower. Method: Twenty-nine patients, 12 with apraxia of speech (AOS; four phonetic and eight prosodic subtype), eight with dysarthria (six hypokinetic and two spastic subtype), and nine patients without any neurogenic MSD completed a standard motor speech evaluation where they were asked to repeat words and sentences, which served as their “natural” speaking rate. They were then asked to repeat lower complexity (counting 1–5; repeating “cat” and “catnip” 3 times each) and higher complexity stimuli (repeating “catastrophe” and “stethoscope” 3 times each and “My physician wrote out a prescription” once) as fast/slow as possible. Word durations and interword intervals were measured. Linear mixed-effects models were used to assess differences related to MSD subtype and stimuli complexity on bidirectional rate modulation capacity as indexed by word duration and interword interval. Articulatory accuracy was also judged and compared. Results: Patients with prosodic AOS demonstrated a reduced ability to go faster; while they performed similarly to patients with spastic dysarthria when counting, patients with spastic dysarthria were able to increase rate similar to controls during sentence repetition; patients with prosodic AOS could not and made increased articulatory errors attempting to increase rate. AOS patients made more articulatory errors relative to other groups, regardless of condition; however, their percentage of errors reduced with an intentionally slowed speaking rate. Conclusions: The findings suggest comparative rate modulation abilities in conjunction with their impact on articulatory accuracy may support differential diagnosis between healthy and abnormal speech and among subtypes of MSDs (i.e., type of dysarthria or AOS). Findings need to be validated in a larger, more representative cohort encompassing several types of MSDs. Supplemental Material: https://doi.org/10.23641/asha.22044632
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection
Sims, Matthew , Khanna, Sahil , Louie, Thomas , Kelly, Colleen , Hohmann, Elizabeth , Wang, Elaine E. L., Oneto, Caterina , Cohen, Stuart H. , Berenson, Charles S., Korman, Louis Y. , Lee, Christine , Lashner, Bret A., Kraft, Colleen S., Ramesh, Mayur , Silverman, Michael H. , Pardi, Darrell S. , Hasson, Brooke , McGovern, Barbara , Moltke, Lisa Von, Investigators, ECOSPOR IV, Hemaidan, Anmar, Kumar, Princy , Misra, Bharat , Nathan, Richard, Pullman, John, Williams, Jeffrey G., Acosta, Idalia, Odio, Alberto, Smith, Kent, Hansen, Val, Georgetson, Michael, Sheikh, Aasim , Arimie, Calin, Andrade, Gladys, O’Marro, Steven, Esfandyari, Tuba, Ritter, Timothy E., Baird, Ian Mcnicol, Colman, Ronald, Hernandez, Lilliam, Adams, Atoya, Walton, Marie, Arsenescu, Razvan, Shapiro, Max, Cook, Paul, Heuer, Marvin, Bogdanovich, Tatiana, Grimard, Doria, Butt, Debra, Gauthier, Stephanie , Guímont, Chantal, Kreines, Michael, Berman, Larry, Bennett, Michael , Fogel, Ronald, Gutierrez, Juan Carlos Moises, Pedersen, P.C. , Bressler, Adam, Nadar, Venkatesh, Newton, Eric, Abbas, Jalal, Jamal, Aamir, Benjamin, Sabrina, Ayub, Kamran, Oguchi, Godson, Pinero, Jose, Ramesh, Gowrappala, Sepe, Paul S., Brook, Loren, Ruthardt, Frederick, Surace, Lindsey, Hussain, Ayub, Rutland, Travis J., Schmalz, Micahel, Degala, Gourisankar, Phillips, Raymond E. , Stock, Kent, Bullock, Jeffrey, Onwueme, Kenolisa, Feuerstadt, Paul , Huang, Edward S. , Lee, Christine H. , Kraft, Colleen S. , Silverman, Michael, De, Ananya, Memisoglu, Asli, Lombardi, David A., Investigators, ECOSPOR IV, Nguyen, Hien , Tran, Huy, Smith, Kent, Weinstock, Leonard B. , Garcia‐Diaz, Julia , Colman, Ronald, Patel, Meenakshi, Shapiro, Max, Cook, Paul, Steiner, Theodore S. , Butt, Debra, Daley, Peter , Gauthier, Stephanie, Berman, Larry, Bennett, Michael, Pedersen, Peder, Newton, Eric, Diaz, Jorge, Abbas, Jalal, DuPont, Herbert L. , Jamal, Aamir, Talreja, Neetu, Ayub, Kamran, Phillips, Raymond

Mayo Clinic

JAMA Network Open | February 13, 2023 | Volume: 6 | Issue: 2 | Pages: e2255758

10.1001/jamanetworkopen.2022.55758 | PMID 36780159 Get It

ImportanceA safe and effective treatment for recurrent Clostridioides difficile infection (CDI) is urgently needed. Antibiotics kill toxin-producing bacteria but do not repair the disrupted microbiome, which promotes spore germination and infection recurrence.ObjectivesTo evaluate the safety and rate of CDI recurrence after administration of investigational microbiome therapeutic SER-109 through 24 weeks.Design, Setting, and ParticipantsThis phase 3, single-arm, open-label trial (ECOSPOR IV) was conducted at 72 US and Canadian outpatient sites from October 2017 to April 2022. Adults aged 18 years or older with recurrent CDI were enrolled in 2 cohorts: (1) rollover patients from the ECOSPOR III trial who had CDI recurrence diagnosed by toxin enzyme immunoassay (EIA) and (2) patients with at least 1 CDI recurrence (diagnosed by polymerase chain reaction [PCR] or toxin EIA), inclusive of their acute infection at study entry.InterventionsSER-109 given orally as 4 capsules daily for 3 days following symptom resolution after antibiotic treatment for CDI.Main Outcomes and MeasuresThe main outcomes were safety, measured as the rate of treatment-emergent adverse events (TEAEs) in all patients receiving any amount of SER-109, and cumulative rates of recurrent CDI (toxin-positive diarrhea requiring treatment) through week 24 in the intent-to-treat population.ResultsOf 351 patients screened, 263 were enrolled (180 [68.4%] female; mean [SD] age, 64.0 [15.7] years); 29 were in cohort 1 and 234 in cohort 2. Seventy-seven patients (29.3%) were enrolled with their first CDI recurrence. Overall, 141 patients (53.6%) had TEAEs, which were mostly mild to moderate and gastrointestinal. There were 8 deaths (3.0%) and 33 patients (12.5%) with serious TEAEs; none were considered treatment related by the investigators. Overall, 23 patients (8.7%; 95% CI, 5.6%-12.8%) had recurrent CDI at week 8 (4 of 29 [13.8%; 95% CI, 3.9%-31.7%] in cohort 1 and 19 of 234 [8.1%; 95% CI, 5.0%-12.4%] in cohort 2), and recurrent CDI rates remained low through 24 weeks (36 patients [13.7%; 95% CI, 9.8%-18.4%]). At week 8, recurrent CDI rates in patients with a first recurrence were similarly low (5 of 77 [6.5%; 95% CI, 2.1%-14.5%]) as in patients with 2 or more recurrences (18 of 186 [9.7%; 95% CI, 5.8%-14.9%]). Analyses by select baseline characteristics showed consistently low recurrent CDI rates in patients younger than 65 years vs 65 years or older (5 of 126 [4.0%; 95% CI, 1.3%-9.0%] vs 18 of 137 [13.1%; 95% CI, 8.0%-20.0%]) and patients enrolled based on positive PCR results (3 of 69 [4.3%; 95% CI, 0.9%-12.2%]) vs those with positive toxin EIA results (20 of 192 [10.4%; 95% CI, 6.5%-15.6%]).Conclusions and RelevanceIn this trial, oral SER-109 was well tolerated in a patient population with recurrent CDI and prevalent comorbidities. The rate of recurrent CDI was low regardless of the number of prior recurrences, demographics, or diagnostic approach, supporting the beneficial impact of SER-109 for patients with CDI.Trial RegistrationClinicalTrials.gov identifier: NCT03183141
Cerebral Revascularization: Bibliometric Analysis of Extracranial-intracranial/intracranial-intracranial Bypass Studies to Date
Durrani, Sulaman , Kreilach, Alec M, Krause, Victoria, Shoushtari, Ali, Nathani, Karim R, Bydon, Mohamad , Kreilach, Alec M., Krause, Victoria, Mualem, William

Mayo Clinic

Journal of the American College of Surgeons | February 13, 2023 | Volume: 236 | Issue: 5 | Pages: S68-S68

10.1097/xcs.0000000000000625 Get It

Rethinking Menopausal Hormone Therapy: For Whom, What, When, and How Long?
Cho, Leslie , Kaunitz, Andrew M., Hayes, Sharonne N. , Lau, Emily S. , Pristera, Nicole , Scott, Nandita S. , Shifren, Jan L. , Shufelt, Chrisandra , Stuenkel, Cynthia A. , Hayes, Sharonne N , Lau, Emily S , Scott, Nandita , Shufelt, Chrisandra L , Lindley, Kathryn J , Faubion, Stephanie S.

Mayo Clinic

Circulation | February 13, 2023 | Volume: 147 | Issue: 7 | Pages: 597-610

10.1161/circulationaha.122.061559 | PMID 36780393 Get It

Menopausal hormone therapy (HT) was widely used in the past, but with the publication of seminal primary and secondary prevention trials that reported an excess cardiovascular risk with combined estrogen-progestin, HT use declined significantly. However, over the past 20 years, much has been learned about the relationship between the timing of HT use with respect to age and time since menopause, HT route of administration, and cardiovascular disease risk. Four leading medical societies recommend HT for the treatment of menopausal women with bothersome menopausal symptoms. In this context, this review, led by the American College of Cardiology Cardiolovascular Disease in Women Committee, along with leading gynecologists, women’s health internists, and endocrinologists, aims to provide guidance on HT use, including the selection of patients and HT formulation with a focus on caring for symptomatic women with cardiovascular disease risk.
Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study
Kumar, Shaji , Bhutani, Divaya , Gertz, Morie A. , Wechalekar, Ashutosh , Comenzo, Raymond L. , Porte, Charles la, Pei, Huiling , Tran, NamPhuong, Dispenzieri, Angela , Gertz, Morie A , Schönland, Stefan , Bhutani, Divaya , Dispenzieri, Angela , Wechalekar, Ashutosh D. , Palladini, Giovanni , Fonseca, Rafaël , Jaccard, Arnaud , Kastritis, Efstathios , Schönland, Stefan , Merlini, Giampaolo

Mayo Clinic

Amyloid | February 13, 2023 | Volume: 30 | Issue: 3 | Pages: 268-278

10.1080/13506129.2022.2164488 | PMID 36779691 Get It

FUS regulates RAN translation through modulating the G-quadruplex structure of GGGGCC repeat RNA in C9orf72-linked ALS/FTD
Fujino, Yuzo , Ishiguro, Taro , Ozawa, Daisaku, Ito, Hayato , Sugiki, Toshihiko , Murata, Asako, Mori, Kohji , Taminato, Tomoya , Koyama, Akihide , Kawabe, Yuya , Takeuchi, Toshihide , Ikeda, Manabu , Mizusawa, Hidehiro, Wada, Keiji , Ishikawa, Kinya , Petrucelli, Leonard , Taguchi, Hideki , Murata, Asako , Ito, Hayato , Sugiki, Toshihiko , Gendron, Tania, Mori, Kohji , Kawabe, Yuya , Fujiwara, Toshimichi , Onodera, Osamu , Taguchi, Hideki , Nagai, Yoshitaka , Ueyama, Morio , Ishiguro, Akira , Gendron, Tania F. , Tokuda, Eiichi , Konno, Takuya , Furukawa, Yoshiaki , Mizuno, Toshiki , Mochizuki, Hideki , Onodera, Osamu , Nakatani, Kazuhiko

Mayo Clinic

eLife | February 13, 2023 | Volume: 12 | Issue: No issue available | Pages: No page available

10.7554/elife.84338 | PMID 37461319 Get It

Abnormal expansions of GGGGCC repeat sequence in the noncoding region of the C9orf72 gene is the most common cause of familial amyotrophic lateral sclerosis and frontotemporal dementia (C9-ALS/FTD). The expanded repeat sequence is translated into dipeptide repeat proteins (DPRs) by noncanonical repeat-associated non-AUG (RAN) translation. Since DPRs play central roles in the pathogenesis of C9-ALS/FTD, we here investigate the regulatory mechanisms of RAN translation, focusing on the effects of RNA-binding proteins (RBPs) targeting GGGGCC repeat RNAs. Using C9-ALS/FTD model flies, we demonstrated that the ALS/FTD-linked RBP FUS suppresses RAN translation and neurodegeneration in an RNA-binding activity-dependent manner. Moreover, we found that FUS directly binds to and modulates the G-quadruplex structure of GGGGCC repeat RNA as an RNA chaperone, resulting in the suppression of RAN translation in vitro. These results reveal a previously unrecognized regulatory mechanism of RAN translation by G-quadruplex-targeting RBPs, providing therapeutic insights for C9-ALS/FTD and other repeat expansion diseases.